SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA - Inserm - Institut national de la santé et de la recherche médicale Accéder directement au contenu
Article Dans Une Revue Nephrology Dialysis Transplantation Année : 2020

SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA

Résumé

No abstract available
Fichier principal
Vignette du fichier
gfz137.pdf (49.24 Ko) Télécharger le fichier

Dates et versions

inserm-03261177 , version 1 (15-06-2021)

Licence

Paternité - Pas d'utilisation commerciale

Identifiants

Citer

P. Sarafidis, C. J. Ferro, E. Morales, A. Ortiz, J. Malyszko, et al.. SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA. Nephrology Dialysis Transplantation, 2020, 35 (10), pp.1825. ⟨10.1093/ndt/gfz137⟩. ⟨inserm-03261177⟩
25 Consultations
542 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More